CN117794548A - 针对bap1及pbrm1中的至少一个的功能下降的肿瘤的药物组合物及抗肿瘤剂 - Google Patents

针对bap1及pbrm1中的至少一个的功能下降的肿瘤的药物组合物及抗肿瘤剂 Download PDF

Info

Publication number
CN117794548A
CN117794548A CN202280052941.2A CN202280052941A CN117794548A CN 117794548 A CN117794548 A CN 117794548A CN 202280052941 A CN202280052941 A CN 202280052941A CN 117794548 A CN117794548 A CN 117794548A
Authority
CN
China
Prior art keywords
cancer
tumor
pbrm1
1and
bap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280052941.2A
Other languages
English (en)
Chinese (zh)
Inventor
佐伯和德
D·瓦格斯
K·张
F·扬库
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of CN117794548A publication Critical patent/CN117794548A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280052941.2A 2021-07-29 2022-07-28 针对bap1及pbrm1中的至少一个的功能下降的肿瘤的药物组合物及抗肿瘤剂 Pending CN117794548A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227035P 2021-07-29 2021-07-29
US63/227,035 2021-07-29
PCT/JP2022/029062 WO2023008511A1 (ja) 2021-07-29 2022-07-28 Ｂａｐ１およびｐｂｒｍ１の少なくとも１つの機能低下を有する腫瘍に対する医薬組成物および抗腫瘍剤

Publications (1)

Publication Number Publication Date
CN117794548A true CN117794548A (zh) 2024-03-29

Family

ID=85087010

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280052941.2A Pending CN117794548A (zh) 2021-07-29 2022-07-28 针对bap1及pbrm1中的至少一个的功能下降的肿瘤的药物组合物及抗肿瘤剂

Country Status (6)

Country Link
US (1) US20240207301A1 (https=)
EP (1) EP4378466A4 (https=)
JP (1) JPWO2023008511A1 (https=)
KR (1) KR20240028451A (https=)
CN (1) CN117794548A (https=)
WO (1) WO2023008511A1 (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038001A1 (en) 1996-04-09 1997-10-16 Yamasa Corporation 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES
RU2559364C2 (ru) 2009-12-18 2015-08-10 Либрамедисина, Инк. СПОСОБ ПОЛУЧЕНИЯ ЗАМЕЩЕННЫХ 1-О-АЦИЛ-2-ДЕЗОКСИ-2-ФТОР-4-ТИО-β-D-АРАБИНОФУРАНОЗ
SG10201603288XA (en) 2012-03-28 2016-05-30 Fujifilm Corp Salt Of 1-(2-Deoxy-2-Fluoro-4-Thio-beta-D-Arabinofuranosyl)Cytosine
KR20170001722A (ko) 2012-08-13 2017-01-04 후지필름 가부시키가이샤 1-(2-데옥시-2-플루오로-4-티오-β-D-아라비노푸라노실)시토신의 합성 중간체, 티오뉴클레오시드의 합성 중간체, 및 그들의 제조법
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
JP6450356B2 (ja) 2016-02-29 2019-01-09 富士フイルム株式会社 液状医薬製剤
IL265044B2 (en) 2016-08-31 2025-02-01 Fujifilm Corp An antitumor preparation containing the substances nab-paclitaxel and 1-(2-deoxy-2-fluoro-4-thio-D-beta-arabinofurnosyl)cytosine, a kit containing these substances and their uses
WO2019146130A1 (ja) 2018-01-29 2019-08-01 富士フイルム株式会社 胆道がん用抗腫瘍剤および胆道がんの処置方法
TW201932120A (zh) 2018-01-29 2019-08-16 日商富士軟片股份有限公司 用於具有異檸檬酸脫氫酶突變的腫瘤的藥物組成物與抗腫瘤劑及其應用
WO2019164010A1 (ja) 2018-02-26 2019-08-29 富士フイルム株式会社 膀胱がん用抗腫瘍剤および膀胱がんの処置方法
WO2019176984A1 (ja) 2018-03-13 2019-09-19 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
WO2019176985A1 (ja) 2018-03-13 2019-09-19 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット

Also Published As

Publication number Publication date
EP4378466A4 (en) 2024-11-20
EP4378466A1 (en) 2024-06-05
US20240207301A1 (en) 2024-06-27
JPWO2023008511A1 (https=) 2023-02-02
WO2023008511A1 (ja) 2023-02-02
KR20240028451A (ko) 2024-03-05

Similar Documents

Publication Publication Date Title
US20230146638A1 (en) Treatment of EGFR-Driven Cancer with Fewer Side Effects
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
JP7523351B2 (ja) 肥満細胞症の治療のための併用療法
US20230277533A1 (en) Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
RU2597844C2 (ru) Введение гипоксически активируемых пролекарств и средств, препятствующих ангиогенезу, для лечения рака
US20180325853A1 (en) Benzoquinone derivative e3330 in combination with chemotherapeutic agents for the treatment of colon cancer
JP6911019B2 (ja) Ｅｇｆｒ−ｔｋｉ耐性を獲得した肺癌の治療薬
US20240108633A1 (en) Method for preventing or treating disease or condition associated with antitumor agent
WO2014050781A1 (ja) Ｒｅｔ阻害剤
JP6911048B2 (ja) がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
CN119564680A (zh) 用于具有特定的基因标志的患者的癌症治疗用药物组合物
EP3849310A1 (en) Combination cancer therapies
KR102382771B1 (ko) 증식성 질환을 위한 조합 치료
CN111836628B (zh) 抗肿瘤剂、抗肿瘤效果增强剂及抗肿瘤用试剂盒
US11141421B2 (en) Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
CN117794548A (zh) 针对bap1及pbrm1中的至少一个的功能下降的肿瘤的药物组合物及抗肿瘤剂
US20100204263A1 (en) Method of treating multidrug resistant cancers
HK40106737A (zh) 针对bap1及pbrm1中的至少一个的功能下降的肿瘤的药物组合物及抗肿瘤剂
CN102215833B (zh) 苯醌衍生物e3330联合化疗剂用于治疗癌症和血管生成
TW202002988A (zh) 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用試劑盒
WO2025262719A1 (en) A composition for treating cancer, methods and use thereof
WO2026039718A1 (en) Cancer treatment using 5,6-dihydro-4h-benzo[de] quinoline-camptothecin
HK40108579A (zh) Kras g12d抑制剂与伊立替康的组合及相关治疗方法
WO2026086864A1 (zh) 一种kat6抑制剂的联合使用
EA048213B1 (ru) Терапевтические комбинации, содержащие ингибиторы убиквитин-специфической протеазы 1 (usp1) и ингибиторы поли(адф-рибоза)полимеразы (parp)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40106737

Country of ref document: HK